All KRAS mutations, namely G12D, G12S, G12V, and Q61H, were confirmed to be truncal events as they were present in all sectors of the tumors, underscoring KRAS mutations’ role as an early driver of tumor initiation (Fig. 1 and Supplementary Table S1). Here, KRAS is linked to neoplasm.